1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
PetVivo Holdings, Inc.

PetVivo Holdings, Inc.

PETVW
PetVivo Holdings, Inc.US flagNASDAQ Capital Market
0.03
USD
+0.00
- -
732,057.00Market Cap
PetVivo Holdings, Inc.
PETVW
(NASDAQ Capital Market)

Recent

price

0.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-4,334.91
-230,062.51
-151,345.5
- -
-56,190.97
-15,574.72
-4,374.69
-952.23
-1,096.45
-711.3
-706.28
-706.28
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
1
1
- -
- -
- -
- -
- -
1
1
Depreciation Expense
- -
- -
- -
- -
-2
-4
-16
-2
-5
-2
-4
-5
-9
-11
-8
-10
-10
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-4,868.99
-218,017.03
-154,790.6
- -
-58,047.21
-28,007.47
-4,338.76
-950.5
-1,130.92
-741.63
-917.45
-917.45
Profit Margin (%)
- -
- -
- -
- -
- -
-1
-1
-1
-1
-1
-1
6
- -
- -
1
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
- -
- -
LT Debt
- -
- -
- -
- -
- -
15
1
- -
-1
-1
-1
6
1
1
4
2
2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
34
36
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
2
1
2
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-128.04%
-78.7%
-47.87%
Free Cash Flow
66.24%
84.54%
3.9%
Net Income, GAAP
50.01%
28.65%
24.7%
Sales/Revenue/Turnover
- -
307.15%
0.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
1
- -
1
2025
- -
- -
1
- -
1
2026
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Abiomed, Inc. (ABMD)
Anteris Technologies Global Corp. (AVR)
Rainmed Medical Limited (2297.HK)
Lattice Biologics Ltd. (LBLTF)
Sonova Holding AG (0QPY.L)
Acarix AB (publ) (ACIXF)
Business
PetVivo Holdings, Inc. (PETVW) is a biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for companion animals and equines, including intra-articular injectable products for lameness, joint pain, and osteoarthritis management; platelet-rich plasma therapies such as PrecisePRP, an off-the-shelf veterinary product delivering 4 billion platelets per vial without blood draws or centrifugation; and a robust pipeline of patented therapies adapting human biomaterials for veterinary applications. The company, founded in 2009 and headquartered in Edina, Minnesota, operates primarily in the United States through distribution networks targeting veterinary clinics and serves markets for dogs, horses, cats, and other pets with veterinarian-administered solutions. Recent developments include a vendor partner agreement with Veterinary Growth Partners accessing 7,300 clinics for expanded therapeutics distribution; an exclusive 10-year licensing deal with Digital Landia Holding Corp. for Agentic Pet AI technology to address client acquisition and Gen Z pet owner engagement via B2B platforms launching in Q1 2026; closure of a $5 million preferred stock offering to accelerate commercialization of Spryng with OsteoCushion Technology and PrecisePRP; and a master agreement with PiezoBioMembrane Inc. enhancing its portfolio of twenty-one patents for animal and human applications.

Company News

APIChatGPT

  • globenewswire.com

    PetVivo Reports Financial and Operational Results for Fiscal 2026

  • globenewswire.com

    PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE YEAR 2026 ENDED MARCH 31, 2026

  • globenewswire.com

    PetVivo Holdings, Inc. to Host Virtual Investor Event

  • globenewswire.com

    PetVivo Reports Results for Third Quarter and First Nine Months of Fiscal 2026